Mirna Therapeutics Inc. (NASDAQ:MIRN) was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday.

A number of other research firms have also weighed in on MIRN. Zacks Investment Research lowered Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 18th. Citigroup Inc. lowered Mirna Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $7.00 to $4.50 in a research note on Tuesday, August 16th. Cantor Fitzgerald lowered Mirna Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. HC Wainwright started coverage on Mirna Therapeutics in a research note on Monday, September 12th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Leerink Swann lowered Mirna Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $10.00 to $4.00 in a research note on Monday, August 15th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Mirna Therapeutics presently has a consensus rating of “Hold” and an average price target of $7.38.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:MIRN)

Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 2.46 on Wednesday. Mirna Therapeutics has a one year low of $2.21 and a one year high of $11.01. The stock has a 50 day moving average of $3.17 and a 200 day moving average of $4.12. The stock’s market cap is $51.25 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mirna-therapeutics-inc-mirn-rating-lowered-to-market-perform-at-oppenheimer-holdings-inc.html

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.